

**FINAL HTA TOPIC PRIORITIZATION LIST 2024 - CYCLE 2 TOPICS***Published as of 23 May 2024 (Thursday)*

Following the stakeholder consultation (23 April 2024), appeals period (12 April to 10 May 2024) on the **provisional HTA Topic Prioritization List 2024 - Cycle 2 Topics**, and processing of 41 appeals, **the HTA Council hereby makes public the FINAL HTA Topic Prioritization List 2024 - Cycle 2 Topics**. These prioritized topics will now be assigned for topic assessment.

Kindly see the list below:

Health Technology		Indication
1	Abacavir + Lamivudine 120mg/ 60mg dispersible tablet	Human immunodeficiency virus (HIV) in pediatric population
2	Alectinib 150mg capsule	Anaplastic lymphoma kinase-positive locally advanced/metastatic Non-Small Cell Lung Cancer (NSCLC)
3	Budesonide + Glycopyrronium + Formoterol 160 mcg/7.2 mcg /4.8 mcg per actuation, pressurized metered dose suspension for inhalation	Chronic obstructive pulmonary disease (COPD) which is not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta agonist (LABA) or combination of a LABA and a long-acting muscarinic antagonist (LAMA)
4	Coagulation Factor VIII -500 units/10mL (50 units/mL) powder solution for IV -1000 units/20mL (50 units/mL) powder solution for IV -2500 units/50mL (50 units/mL) powder solution for IV	Hemophilia A in the pediatric population
5	Chip-based RT-PCR MTB test (<i>TrueNat</i>)	Drug-susceptible tuberculosis (DS-TB)
6	Chip-based RT-PCR MTB- RIF test (<i>TrueNat MTB Plus</i> , <i>TrueNat MTB-RIF</i>)	Rifampicin-resistant tuberculosis (RR-TB)/ Multi-drug resistant tuberculosis (MDR-TB)
7	Cinacalcet (<i>as hydrochloride</i>) 30mg film-coated tablet	Secondary hyperparathyroidism in patients with chronic kidney disease (CKD)
8	Dapivirine Vaginal Ring 25 mg vaginal delivery system	HIV pre-exposure prophylaxis (PrEP)
9	Dexmedetomidine (<i>as hydrochloride</i>) - 100 mcg/ mL (200 mcg/ 2mL) Concentrate for Intravenous Infusion, 2mL glass vial - 4 mcg/mL in 0.9% w/v Sodium Chloride Solution for intravenous infusion (premixed), 50 mL glass bottle	Intensive Care Unit (ICU) sedation, procedural sedation


10	Dibencozide 1 mg capsule	Premature neonates and low birth weight neonates
11	Donepezil hydrochloride 23 mg film-coated tablet	Moderate to severe Alzheimer's Disease
12	Durvalumab - 120mg/ 2.4mL (50mg/mL), 10 mL vial concentrate for solution for IV infusion - 500mg/ 10mL (50mg/mL), 10 mL vial concentrate for solution for IV infusion	Locally advanced NSCLC
13	Edoxaban - 30 mg film-coated tablet - 60 mg film-coated tablet	Acute Ischemic Stroke in adults with nonvalvular atrial fibrillation
14	Eribulin 500 mcg/mL (1mg/ 2mL), 5 mL vial solution for injection (IV)	Metastatic human epidermal growth factor receptor 2 (HER2)-negative breast cancer
15	Eribulin 500 mcg/mL (1mg /2mL), 5 mL vial solution for injection (IV)	Metastatic triple negative breast cancer
16	Exemestane 25 mg tablet	Hormone-receptor positive advanced breast cancer (ABC) in women with natural or induced postmenopausal status
17	Factor VIII Inhibitor Bypassing Activity - 500U/10mL powder solution for infusion (IV) - 1000U/20mL powder solution for infusion (IV) - 2500U/50mL powder solution for infusion (IV)	Hemophilia B with inhibitors
18	Factor VIII Inhibitor Bypassing Activity 500U/10mL powder solution for infusion (IV) - 1000U/20mL powder solution for infusion (IV) - 2500U/50mL powder solution for infusion (IV)	Hemophilia A with inhibitors
19	Fluticasone/Umeclidinium/vilanterol - 100mcg/62.5mcg/25mcg dry powder for inhalation	Moderate to Severe COPD
20	Fulvestrant 250mg/ 5mL, 5mL single-dose pre-filled syringe for injection	Advanced/metastatic hormone positive breast cancer
21	Gadoxetic acid (Disodium) 0.25 mmol/mL, 10 mL solution for injection	T1-weighted magnetic resonance imaging of the liver
22	Gefitinib 250 mg film-coated tablet	Locally advanced/metastatic NSCLC with activating mutations of epidermal growth factor receptor (EGFR)
23	Glucose (544mL) + Amino Acids (315mL) + Electrolytes + Lipids (141mL), 1000 mL emulsion for IV infusion	Disease-related malnutrition in hospitalized patients
24	Hexavalent vaccine (Diphtheria, Tetanus, Acellular pertussis, Inactivated Poliomyelitis and <i>Haemophilus influenzae</i> Type B conjugate vaccine, adsorbed) 1 ml Type I glass pre-filled syringe (DTPa-HBV-IPV component) + 3 mL type I glass vial (Hib component)	Active immunization of infants and toddlers to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to <i>Haemophilus influenzae</i> type b
25	High Protein (as Semi Modular Enteral Nutrition) 400g tin can, 25g aluminum sachet & 400g plastic jar	Protein supplementation
26	HIV Self Test Kit	HIV screening


27	HIV/Syphilis Duo test	HIV and Syphilis detection
28	Human papillomavirus (HPV) vaccine 9-valent (types 6, 11, 16, 18, 31, 33, 45, 52, 58) - Recombinant vaccine, 0.5mL suspension for intramuscular injection in 1.5 mL syringe - Recombinant vaccine, 0.5 mL single-dose vial	HPV-related infection and cancer
29	Ibuprofen - 400 mg/4mL, 6 mL vial for IV infusion - 800 mg/8mL, 10mL vial for IV infusion	Pediatric patients six months and older for the: - Management of mild to moderate pain - Management of moderate to severe pain as an adjunct to opioid analgesics
30	Icodextrin (Extraneal 7.5%) peritoneal dialysis solution, 2L Ambuflex container (single bag); 2L Ultrabag (twin bag)	End Stage Renal Disease (ESRD) requiring home dialysis
31	Inclisiran 284 mg/ 1.5 mL solution for injection (SC), 2.25 mL prefilled syringe	Hypercholesterolemia/ dyslipidemia among adults with previous cardiovascular event
32	Inclisiran 284 mg/ 1.5 mL solution for injection (SC), 2.25 mL prefilled syringe	Hypercholesterolemia/ dyslipidemia among adults with Type 2 Diabetes Mellitus who have not had a cardiovascular event
33	Insulin glargine 300 units/mL (equivalent to 10.91 mg/mL) solution for Injection, 1.5 mL prefilled syringe	Type 1 Diabetes Mellitus
34	Insulin glargine 300 units/mL (equivalent to 10.91 mg/mL) solution for injection, 1.5 mL prefilled syringe	Type 2 Diabetes Mellitus
35	Insulin glargine + Lixisenatide - 3.64 mg (equivalent to 100 Units of insulin glargine)/ 33 mcg per mL solution for injection, 3 mL cartridge - 3.64 mg (equivalent to 100 Units of insulin glargine)/ 50 mcg per mL solution for injection, 3 mL cartridge	Type 2 Diabetes Mellitus
36	Interferon gamma release ELISA assay (IGRA) (<i>QuantiFERON-TB Gold Plus [QFT-Plus]</i>)	Detection of latent/ asymptomatic tuberculosis
37	Irbesartan + Amlodipine - 150mg/ 5mg film-coated tablet - 300mg/ 5mg film-coated tablet - 300mg/ 10mg film-coated tablet	Essential hypertension
38	Lateral flow uterine lipoarabinomannan assay (LF-LAM)	Active mycobacterial infection in HIV patients
39	Levonorgestrel 75mg Subdermal implant	Contraception
40	Levonorgestrel (52mg) Intrauterine Device (IUD)	Contraception
41	Line Probe Assay (<i>GenoType MTBDR-Plus</i>)	RR-TB/ MDR-TB
42	Line Probe Assay (<i>GenoType MTBDRsl</i>)	Extensively drug-resistant (XDR) <i>Mycobacterium tuberculosis</i> complex tuberculosis
43	Lorlatinib 25 mg and 100 mg tablets	Anaplastic lymphoma kinase-positive advanced NSCLC

44	Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine 5 mcg Lyophilized Powder for Solution for Injection (IM) in clear glass vial + 0.5 mL prefilled glass syringe (0.9% Sodium Chloride as diluent) with 2 separate needles	Active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by <i>Neisseria meningitidis</i> group A, C, W-135 and Y
45	Multiple Micronutrient Supplement Capsule for Pregnant and Lactating Women	Prevention of vitamin and mineral deficiencies; improve iron status, and reduce anemia among pregnant and lactating women
46	Olaparib - 100 mg film-coated tablet - 150 mg film-coated tablet	Newly diagnosed advanced BRCA-mutated, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to first-line platinum-based chemotherapy
47	Osimertinib - 80 mg Tablet - 40 mg Tablet	Adjuvant treatment after tumor resection in patients with NSCLC whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
48	Pancreatin 150mg capsule	Pancreatic Exocrine Insufficiency (PEI)
49	Parecoxib 40 mg Lyophilized Powder for IM/IV Injection	Short-term treatment of acute pain and post-operative pain
50	Pertuzumab 30 mg/mL (420 mg/14 mL) concentrate for solution for infusion, 14mL single-use vial	HER2-positive metastatic or locally recurrent unresectable breast cancer
51	Pertuzumab + Trastuzumab - 1200 mg + 600 mg per 15 mL, 20 mL vial solution for injection (SC) - 600 mg + 600 mg/10 mL, 15 mL vial solution for injection (SC)	Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early breast cancer
52	Polatuzumab 140 mg powder concentrate for solution for infusion (IV)	Treatment of adult patients with diffuse large B-cell lymphoma who have received at least one prior therapy
53	Rosuvastatin (as calcium) + Ezetimibe - 10mg/ 10mg film-coated Tablet - 20mg/ 10mg film-coated Tablet	Reduction of risk of cardiovascular events in patients with coronary heart diseases (CHD) and a history of acute coronary syndrome (ACS)
54	RT- PCR MDR-TB Assay (BD MAX MDR-TB Assay)	RR-TB/MDR-TB/Isoniazid-resistant-TB (inhA and KatG identification)
55	RT-PCR MTB/RIF Ultra Assay (Cepheid Xpert)	RR-TB/MDR-TB
56	RT-PCR MTB/XDR Assay (Cepheid Xpert)	XDR <i>M. tuberculosis</i> complex tuberculosis
57	Sentosa SQ HIV Sentosa® SQ HIV Genotyping Assay (4x16)	HIV subtypes and genetic variants in patients diagnosed with HIV infection
58	38% Silver diamine fluoride	Prevention and arrest of dentin caries

	-25% silver, 8% ammonia, 5% fluoride in water base in 5ml bottle	
59	Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate 1.544 g/83.16 mg/ 63.13 powder for reconstitution	Sinusitis
60	Somatropin - 5.3mg/mL Powder and Solvent for Solution for Injection (SC) - 12mg/mL Powder and Solvent for Solution for Injection (SC)	Growth disturbance due to insufficient secretion of growth hormone among pediatric patients
61	Tenofovir + Lamivudine + Dolutegravir (TLD) 300mg / 300 mg / 50 mg tablet	HIV treatment for treatment-experienced people living with HIV (PLHIV) (including those that are stable in their current regimen)
62	Tenofovir + Lamivudine 300mg / 300mg tablet <i>In combination with</i> Dolutegravir 50 mg tablet	HIV treatment for treatment-experienced PLHIV (including those that are stable in their current regimen)
63	Zinc Oxide + Calamine 555.7 mg/ 164.5 mg, per 3.5 g Topical Ointment	Incontinence-induced dermatitis
64	Zinc Oxide + Calamine 555.7 mg/ 164.5 mg, per 3.5 g Topical Ointment	Diaper dermatitis

for


ANNE JULIENNE GENUINO-MARFORI, RPh, MSc
 Division Chief
 HTA Division


MARITA V. TOLENTINO-REYES, MD
 Chairperson
 HTA Council